The effect of palifermin on chemotherapy- and radiation therapy-induced mucositis: A review of the current literature

Supportive Cancer Therapy

Volumn 4, Issue 4, 2007, Pages 188-197

  Beaven, Anne W ^a   Shea, Thomas C ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Autologous stem cell transplantation; Hematopoietic stem cell transplantation; Recombinant human keratinocyte growth factor

Indexed keywords

BUSULFAN; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; KERATINOCYTE GROWTH FACTOR; METHOTREXATE; MORPHINE; PALIFERMIN; TACROLIMUS;

AMYLASE BLOOD LEVEL; CLINICAL TRIAL; COLORECTAL CANCER; DIZZINESS; DRUG MECHANISM; DYSPHAGIA; ERYTHEMA; FEBRILE NEUTROPENIA; GRAFT VERSUS HOST REACTION; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; KIDNEY DYSFUNCTION; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NONHUMAN; PHARMACODYNAMICS; PHARYNX DISEASE; PRURITUS; RASH; REVIEW; SIDE EFFECT; SKIN EDEMA; STOMATITIS; TASTE DISORDER; TONGUE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR GROWTH; XEROSTOMIA;

EID: 35349012312     PISSN: 15432912     EISSN: None     Source Type: Journal    
DOI: 10.3816/SCT.2007.n.014     Document Type: Review

References (58)

1. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351:2590-2598.
2. Bellm LA, Epstein JB, Rose-Ped A, et al. Patient reports of complications of bone marrow transplantation. Support Care Cancer 2000; 8:33-39.
3. Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001; 19:2201-2205.
4. Rapoport AP, Miller Watelet LF, Linder T, et al. Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Oncol 1999; 17:2446-2453.
5. Nikoletti S, Hyde S, Shaw T, et al. Comparison of plain ice and flavoured ice for preventing oral mucositis associated with the use of 5 fluorouracil. J Clin Nurs 2005; 14:750-753.
6. Nottage M, McLachlan SA, Brittain MA, et al. Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial. Support Care Cancer 2003; 11:41-47.
7. Gabriel DA, Shea TC, Serody JS, et al. Cytoprotection by amifostine during autologous stem cell transplantation for advanced refractory hematologic malignancies. Biol Blood Marrow Transplant 2005; 11:1022-1030.
8. Crawford J, Tomita DK, Mazanet R, et al. Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy. Cytokines Cell Mol Ther 1999; 5:187-193.
9. Valcarcel D, Sanz MA, Jr, Sureda A, et al. Mouth-washings with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) do not improve grade III-IV oropharyngeal mucositis (OM) in patients with hematological malignancies undergoing stem cell transplantation. Results of a randomized double-blind placebo-controlled study. Bone Marrow Transplant 2002; 29:783-787.
10. Masucci G, Broman P, Kelly C, et al. Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy: a multicenter open randomized phase III study. Med Oncol 2005; 22:247-256.
11. Sonis ST. A biological approach to mucositis. J Support Oncol 2004; 2:21-32; discussion 5-6.
12. Rubin JS, Osada H, Finch PW, et al. Purification and characterization of a newly identified growth factor specific for epithelial cells. Proc Natl Acad Sci U S A 1989; 86:802-806.
13. Finch PW, Rubin JS, Miki T, et al. Human KGF is FGF-related with properties of a paracrine effector of epithelial cell growth. Science 1989; 245:752-755.
14. Kepivance® [package insert]. Thousand Oaks, CA: Amgen Inc; 2005.
15. Braun S, Hanselmann C, Gassmann MG, et al. Nrf2 transcription factor, a novel target of keratinocyte growth factor action which regulates gene expression and inflammation in the healing skin wound. Mol Cell Biol 2002; 22:5492-5505.
16. Ptitsyn LR, Al'tman IB, Gurov MV, et al. Production of recombinant human ketatinocyte growth factor in Escherichia coli cells [in Russian]. Bioorg Khim 1998; 24:523-529.
17. Blijlevens N, Sonis S. Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis. Ann Oncol 2007; 18:817-826.
18. Potten CS, Booth D, Cragg NJ, et al. Cell kinetic studies in the murine ventral tongue epithelium: mucositis induced by radiation and its protection by pretreatment with keratinocyte growth factor (KGF). Cell Prolif 2002; 35(suppl 1):32-47.
19. Terry NH, Brinkley J, Doig AJ, et al. Cellular kinetics of murine lung: model system to determine basis for radioprotection with keratinocyte growth factor. Int J Radiat Oncol Biol Phys 2004; 58:435-444.
20. Zia-Amirhosseini P, Salfi M, Leese P, et al. Pharmacokinetics, pharmacodynamics, and safety assessment of palifermin (rHuKGF) in healthy volunteers. Clin Pharmacol Ther 2006; 79:558-569.
21. Panoskaltsis-Mortari A, Ingbar DH, Jung P, et al. KGF pretreatment decreases B7 and granzyme B expression and hastens repair in lungs of mice after allogeneic BMT. Am J Physiol Lung Cell Mol Physiol 2000; 278:L988-L999.
22. Ray P, Devaux Y, Stolz DB, et al. Inducible expression of keratinocyte growth factor (KGF) in mice inhibits lung epithelial cell death induced by hyperoxia. Proc Natl Acad Sci U S A 2003; 100:6098-6103.
23. Chang Y, Wang J, Lu X, et al. KGF induces lipogenic genes through a PI3K and JNK/SREBP-1 pathway in H292 cells. J Lipid Res 2005; 46:2624-2635.
24. Bao S, Wang Y, Sweeney P, et al. Keratinocyte growth factor induces Akt kinase activity and inhibits Fas-mediated apoptosis in A549 lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2005; 288:L36-L42.
25. Takeoka M, Ward WF, Pollack H, et al. KGF facilitates repair of radiation-induced DNA damage in alveolar epithelial cells. Am J Physiol 1997; 272(6 part 1):L1174-L1180.
26. Zia-Amirhosseini P, Salfi M, Elhardt D, et al. Pharmacokinetics (PK) of 2 dosing regimens of palifermin in patients with hematologic malignancies undergoing high-dose chemoradiotherapy and hematopoietic stem cell transplantation. Blood 2005; 106:1256a (Abstract #5294).
27. Gillespie B, Zia-Amirhosseini P, Salfi M, et al. Effect of renal function on the pharmacokinetics of palifermin. J Clin Pharmacol 2006; 46:1460-1468.
28. Rosen LS, Abdi E, Davis ID, et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol 2006; 24:5194-5200.
29. Brizel DM, Le QT, Rosenthal D, et al. Phase 2 study of recombinant human keratinocyte growth factor in head & neck cancer treated with standard or hyperfractionated irradiation & concurrent chemotherapy. Int J Radiat Oncol Biol Phys 2002; 54:285-286 (Abstract #2128).
30. Brizel DM, Herman T, Goffinet D, et al. A phase I/II trial of escalating doses of recombinant human keratinocyte growth factor in head & neck cancer patients receiving radiotherapy with concurrent chemotherapy. Int J Radiat Oncol Biol Phys 2001; 51:40 (Abstract #67).
31. Meropol NJ, Somer RA, Gutheil J, et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol 2003; 21:1452-1458.
32. Blazar BR, Weisdorf DJ, Defor T, et al. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 2006; 108:3216-3222.
33. Shea TC, Kewalramani T, Mun Y, et al. Evaluation of single-dose palifermin to reduce oral mucositis in fractionated total body irradiation and high dose chemotherapy with autologous peripheral blood progenitor cell transplantation. Blood 2006; 108:875a (Abstract #3073).
34. Reynolds CM, Levine JE, Uberti JP, et al. Keratinocyte growth factor factor (palifermin) in combination with tacrolimus and methotrexate for the prevention of acute graft-vs-host disease in patients at high risk of aGVHD. Blood 2004; 104:343a (Abstract #1228).
35. Spielberger R, Stiff P, Emmanouilides C, et al. Efficacy of recombinant human keratinocyte growth factor in reducing mucositis in patients with hematologic malignancies undergoing autologous peripheral blood progenitor cell transplantation after radiation-based conditioning - results of a phase 2 trial. Proc Am Soc Clin Oncol 2001; 20:3 (Abstract #25).
36. Stiff PJ, Erder H, Bensinger WI, et al. Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant 2006; 37:393-401.
37. Stiff PJ, Emmanouilides C, Bensinger WI, et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol 2006; 24:5186-5193.
38. Krijanovski OI, Hill GR, Cooke KR, et al. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Blood 1999; 94:825-831.
39. Vanclee A, Lutgens LC, Oving EB, et al. Keratinocyte growth factor ameliorates acute graft-versus-host disease in a novel nonmyeloablative haploidentical transplantation model. Bone Marrow Transplant 2005; 36:907-915.
40. Panoskaltsis-Mortari A, Taylor PA, Rubin JS, et al. Keratinocyte growth factor facilitates alloengraftment and ameliorates graft-versus-host disease in mice by a mechanism independent of repair of conditioning-induced tissue injury. Blood 2000; 96:4350-4356.
41. Rossi S, Blazar BR, Farrell CL, et al. Keratinocyte growth factor preserves normal thymopoiesis and thymic microenvironment during experimental graft-versus-host disease. Blood 2002; 100:682-691.
42. Min D, Taylor PA, Panoskaltsis-Mortari A, et al. Protection from thymic epithelial cell injury by keratinocyte growth factor: a new approach to improve thymic and peripheral T-cell reconstitution after bone marrow transplantation. Blood 2002; 99:4592-4600.
43. Seggewiss R, Lore K, Guenaga FJ, et al. Keratinocyte growth factor augments immune reconstitution after autologous hematopoietic progenitor cell transplantation in rhesus macaques. Blood 2007; 110:441-449.
44. Nasilowska-Adamska B, Rzepecki P, Manko J, et al. The significance of palifermin (Kepivance) in reduction of oral mucositis incidence and acute graft versus host disease in patients with hematological diseases undergoing HSCT. Bone Marrow Transplant 2006; 13:77-78B.
45. Krenger W, Hill GR, Ferrara JL. Cytokine cascades in acute graft-versus-host disease. Transplantation 1997; 64:553-558.
46. Hill GR, Crawford JM, Cooke KR, et al. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90:3204-3213.
47. Bensadoun RJ, Benezery K, Dassonville O, et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys 2006; 64:983-994.
48. Oelmann E, Haghgu S, Kulimova E, et al. Influence of keratinocyte growth factor on clonal growth of epithelial tumor cells, lymphoma and leukemia cells and on sensitivity of tumor cells towards 5-fluorouracil in vitro. Int J Oncol 2004; 25:1001-1012.
49. Ropiquet F, Huguenin S, Villette JM, et al. FGF7/KGF triggers cell transformation and invasion on immortalised human prostatic epithelial PNT1A cells. Int J Cancer 1999; 82:237-243.
50. Zang XP, Pento JT. Keratinocyte growth factor-induced motility of breast cancer cells. Clin Exp Metastasis 2000; 18:573-580.
51. Nguyen TN, Zang XP, Pento JT. Keratinocyte growth factor stimulates the migration and proliferation of breast cancer cells in a culture wounding model. Pharmacol Res 2002; 46:179-183.
52. Ning S, Shui C, Khan WB, et al. Effects of keratinocyte growth factor on the proliferation and radiation survival of human squamous cell carcinoma cell lines in vitro and in vivo. Int J Radiat Oncol Biol Phys 1998; 40:177-187.
53. Hille A, Rave-Frank M, Pradier O, et al. Effect of keratinocyte growth factor on the proliferation, clonogenic capacity and colony size of human epithelial tumour cells in vitro. Int J Radiat Biol 2003; 79:119-128.
54. Okunieff P, Fenton BM, Zhang L, et al. Fibroblast growth factors (FGFS) increase breast tumor growth rate, metastases, blood flow and oxygenation without significant change in vascular density. In: Dunn JF, Swartz HM, eds. Oxygen Transport to Tissue XXIV. New York, NY: Kluwer Academic/Plenum Publishers; 2003:593-601.
55. Gibson RJ, Keefe DM, Clarke JM, et al. The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. Cancer Chemother Pharmacol 2002; 50:53-58.
56. Matsunobu T, Ishiwata T, Yoshino M, et al. Expression of keratinocyte growth factor receptor correlates with expansive growth and early stage of gastric cancer. Int J Oncol 2006; 28:307-314.
57. Spielberger R, Emmanouilides C, Bensinger W, et al. Long-term survival is comparable between palifermin-treated and placebo-treated patients with hematologic malignancies undergoing high-dose chemotherapy and total body irradiation followed by autologous hematopoietic stem cell transplantation. Blood 2005; 106:828a (Abstract #2925).
58. Okunieff P, Li M, Liu W, et al. Keratinocyte growth factors radioprotect bowel and bone marrow but not KHT sarcoma. Am J Clin Oncol 2001; 24:491-495.